### Analysis:
Johnson & Johnson reported strong Q2 2023 results, with adjusted operational sales growth of 7.5% and adjusted operational EPS growth of 9.7%. The company raised its full-year guidance, projecting sales of $99.3 billion to $100.3 billion and EPS of $10.60 to $10.70. The MedTech segment delivered 14.7% operational growth, while the Pharmaceuticals segment saw 6.2% growth. The company also announced a potential split-off of Kenvue shares through an exchange offer. The outlook remains positive, but concerns about the IRA and potential impacts on drug pricing and innovation persist.

### Conclusion:
The stock is likely to experience a **positive impact** in the short term due to the strong earnings report and raised guidance. However, the potential impacts of the IRA could introduce uncertainty and negativity in the longer term.

**Rating: 1**